Literature DB >> 33504023

Early and Late Postoperative Seizures in Meningioma Patients and Prediction by a Recent Scoring System.

Peter Baumgarten1, Mana Sarlak1, Daniel Monden1, Andrea Spyrantis1, Simon Bernatz2, Florian Gessler1, Daniel Dubinski1, Elke Hattingen3, Gerhard Marquardt1, Adam Strzelczyk4,5,6, Felix Rosenow4,5,6, Patrick N Harter2,6,7,8,9, Volker Seifert1, Thomas M Freiman1,4,6.   

Abstract

Seizures are among the most common symptoms of meningioma. This retrospective study sought to identify risk factors for early and late seizures in meningioma patients and to evaluate a modified STAMPE2 score. In 556 patients who underwent meningioma surgery, we correlated different risk factors with the occurrence of postoperative seizures. A modified STAMPE2 score was applied. Risk factors for preoperative seizures were edema (p = 0.039) and temporal location (p = 0.038). For postoperative seizures preoperative tumor size (p < 0.001), sensomotory deficit (p = 0.004) and sphenoid wing location (p = 0.032) were independent risk factors. In terms of postoperative status epilepticus; sphenoid wing location (p = 0.022), tumor volume (p = 0.045) and preoperative seizures (p < 0.001) were independent risk factors. Postoperative seizures lead to a KPS deterioration and thus an impaired quality of life (p < 0.001). Late seizures occurred in 43% of patients with postoperative seizures. The small sub-cohort of patients (2.7%) with a STAMPE2 score of more than six points had a significantly increased risk for seizures (p < 0.001, total risk 70%). We concluded that besides distinct risk factors, high scores of the modified STAMPE2 score could estimate the risk of postoperative seizures. However, it seems not transferable to our cohort.

Entities:  

Keywords:  STAMPE2; anticonvulsants; epilepsy; meningioma; seizures

Year:  2021        PMID: 33504023      PMCID: PMC7865990          DOI: 10.3390/cancers13030450

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  33 in total

1.  The recurrence of intracranial meningiomas after surgical treatment.

Authors:  D SIMPSON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1957-02       Impact factor: 10.154

2.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

Authors:  Quinn T Ostrom; Haley Gittleman; Peter Liao; Chaturia Rouse; Yanwen Chen; Jacqueline Dowling; Yingli Wolinsky; Carol Kruchko; Jill Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

3.  Outcomes after discontinuation of antiepileptic drugs after surgery in patients with low grade brain tumors and meningiomas.

Authors:  Rohit R Das; Elinor Artsy; Shelley Hurwitz; Patrick Y Wen; Peter Black; Alexandra Golby; Barbara Dworetzky; Jong Woo Lee
Journal:  J Neurooncol       Date:  2012-01-03       Impact factor: 4.130

4.  Brain invasion in otherwise benign meningiomas does not predict tumor recurrence.

Authors:  Peter Baumgarten; Florian Gessler; Jens Schittenhelm; Marco Skardelly; Dominique S Tews; Christian Senft; Maika Dunst; Lioba Imoehl; Karl H Plate; Marlies Wagner; Joachim P Steinbach; Volker Seifert; Michel Mittelbronn; Patrick N Harter
Journal:  Acta Neuropathol       Date:  2016-07-27       Impact factor: 17.088

5.  Long-term control and predictors of seizures in intracranial meningioma surgery: a population-based study.

Authors:  Hai Xue; Olafur Sveinsson; Jiri Bartek; Petter Förander; Simon Skyrman; Lars Kihlström; Raana Shafiei; Tiit Mathiesen; Torbjörn Tomson
Journal:  Acta Neurochir (Wien)       Date:  2018-01-11       Impact factor: 2.216

6.  Predicting outcome of epilepsy after meningioma resection.

Authors:  Hans-Georg Wirsching; Corinne Morel; Corinne Gmür; Marian Christoph Neidert; Christian Richard Baumann; Antonios Valavanis; Elisabeth Jane Rushing; Niklaus Krayenbühl; Michael Weller
Journal:  Neuro Oncol       Date:  2015-12-18       Impact factor: 12.300

7.  Factors Associated With Pre- and Postoperative Seizures in 1033 Patients Undergoing Supratentorial Meningioma Resection.

Authors:  William C Chen; Stephen T Magill; Dario J Englot; Joe D Baal; Sagar Wagle; Jonathan W Rick; Michael W McDermott
Journal:  Neurosurgery       Date:  2017-08-01       Impact factor: 4.654

8.  Seizure control for patients undergoing meningioma surgery.

Authors:  Kaisorn L Chaichana; Courtney Pendleton; Hasan Zaidi; Alessandro Olivi; Jon D Weingart; Gary L Gallia; Michael Lim; Henry Brem; Alfredo Quiñones-Hinojosa
Journal:  World Neurosurg       Date:  2012-03-30       Impact factor: 2.104

9.  Anatomic location is a risk factor for atypical and malignant meningiomas.

Authors:  Ari J Kane; Michael E Sughrue; Martin J Rutkowski; Gopal Shangari; Shanna Fang; Michael W McDermott; Mitchel S Berger; Andrew T Parsa
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

10.  Peritumoral edema and seizure in patients with cerebral convexity and parasagittal meningiomas.

Authors:  T Kawaguchi; S Kameyama; R Tanaka
Journal:  Neurol Med Chir (Tokyo)       Date:  1996-08       Impact factor: 1.742

View more
  3 in total

Review 1.  Meningioma Related Epilepsy- Pathophysiology, Pre/postoperative Seizures Predicators and Treatment.

Authors:  Rasha Elbadry Ahmed; Hailiang Tang; Anthony Asemota; Lei Huang; Warren Boling; Firas Bannout
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

2.  Incidence, risk factors, and outcomes for early postoperative seizures in dogs with rostrotentorial brain tumors after intracranial surgery.

Authors:  Rell L Parker; John Du; Richard L Shinn; Adam G Drury; Fang-Chi Hsu; John L Roberston; Thomas E Cecere; Avril U Arendse; John H Rossmeisl
Journal:  J Vet Intern Med       Date:  2022-02-15       Impact factor: 3.333

3.  The Occurrence and Relationship of Postoperative Seizure and de novo Epilepsy after Craniotomy Surgery: A Retrospective Single-Center Cohort Study.

Authors:  Sayaka Horiuchi; Kohei Kanaya; Tetsuyoshi Horiuchi
Journal:  Front Surg       Date:  2022-04-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.